Abstract We investigated whether exposure to sub-lethal concentrations of chlorhexidine digluconate (CHG) changed the response of five Staphylococcus spp. to human β-Defensin-3 (hBD-3). The change in response for each strain was determined in vitro with time-kill experiments in suspension by comparing the mean log 10 reduction caused by hBD-3 at 1.5 and 3 h in exposed and non-exposed bacteria. The identity of staphylococcal species was verified by DNA sequence homology in the gyrA genes in comparison with reference strains. Baseline sub-lethal concentrations allowing visible bacterial growth were between 0.0625 and 0.25 μg/ml. Sub-lethal CHG concentrations increased within 3 days in two isolates. For S. capitis 19/2, CHG-exposed cells were less susceptible to 0.5 μg/ml hBD-3 (log 10 reduction 0.78 versus 2.06 at 1.5 h; p<0.001; t-test). For S. aureus, however, CHG-exposed cells were more susceptible to 1 μg/ml hBD-3. The observed changes between CHG-exposed and nonexposed cells did not indicate a general trend in response to hBD-3. Overall, we found no consistent evidence that 3 days of exposure to CHG changed the response of five Staphylococcus spp. to hBD-3. The use of CHG for skin antisepsis is, based on our data, unlikely to change the natural defence activity of hBD-3.
Background
One of the main functions of the skin is to protect the host from microbial infections; however, the skin itself is a potential source of endogenous infections. The skin has established different physiological mechanisms to prevent infections, which can be caused by resident and transient skin microorganisms. Firstly, it acts as a physical barrier. In addition, the skin shows a diversity of immune-relevant processes to control the microbial ecology present on human skin.
One important mechanism for controlling colonisation of the skin is the secretion of constitutively or inducibly expressed antimicrobial peptides (AMPs), which are part of the innate immune system. These peptides are effective against pathogenic microorganisms and some of them, e.g. defensins, are multifunctional signalling molecules that trigger adaptive immune responses [1] .
Human β-Defensin-3 (hBD-3), a cationic, broadspectrum AMP of the defensin family, is one of the AMPs with multiple biological functions [2, 3] . In contrast to human β-Defensin-1 and -2, hBD-3 shows potent antimicrobial activity against Gram-positive bacteria. These include Staphylococcus aureus [4, 5] , which is one of the most common causes of nosocomial infections, such as catheter-related bloodstream infections [6, 7] , but also multidrug-resistant (MDR) nosocomial pathogens, e.g. methicillin-resistant S. aureus (MRSA) and vancomycin-resistant enterococci [4, 8] . The hBD-3 peptide is inducibly expressed by keratinocytes of the human skin [9] . Various stimuli which influence hBD-3 expression have been identified, e.g. the upregulation of hBD-3 expression is associated with inflammatory skin diseases like psoriasis. An enhanced amount of hBD-3 has been found after contact of the skin with bacteria [3, 4, 10] . In addition, current research findings have shown that sterile wounding of the skin may also result in increased hBD-3 expression [11] .
Maisetta et al. investigated synergisms in antimicrobial activity between hBD-3 and other antibiotics against oral bacteria. They showed that a combination of chlorhexidine with hBD-3 had a beneficial antibacterial effect [12] .
Chlorhexidine digluconate (CHG) is used in skin antisepsis during the placement of central venous catheters (CVCs). This is in accordance with recommendations of the Centers for Disease Control (CDC) to use alcohol or a 2% chlorhexidine-based preparation for this procedure [7] . In a previous study, we were able to show that CHG in propan-1-ol slows down recolonisation of the skin for at least 72 h [13] . We, therefore, assumed that CHG persists on the skin for at least 3 days after application when the skin is covered with an adhesive dressing after evaporation of the alcohol.
CVCs may remain in place for an average of 6-28 days and dressings are changed several times during this period [14] . Normally, the skin around the catheter site is treated with a CHG-containing antiseptic repeatedly every time the catheter dressing is changed. Thus, the skin bacteria at the catheter site are permanently exposed to CHG and the physical skin barrier, which is essential for protection of the bloodstream against microorganisms, is permanently disrupted for a long period of time. The results of Sørensen et al. showed that the concentration of hBD-3 increases within 4 days after sterile wounding [11] ; therefore, we assumed that the bacteria are first exposed to CHG for at least 3 days before the hBD-3 concentration on skin increases.
It has been reported that different bacterial species are able to adapt to sub-lethal concentrations of CHG [15] [16] [17] [18] [19] [20] and that this adaptation affects the susceptibility to different biocides [21] and antibiotics in Pseudomonas stutzeri [16, 21, 22] . Moore et al. showed that different skin bacteria were able to adapt to CHG after repeated exposure [23] .
To the best of our knowledge, there are no studies on whether CHG exposure changes the response of Grampositive bacteria to antimicrobial peptides, such as hBD-3.
The aims of this study were to analyse, using in vitro time-kill studies, whether exposure to CHG at sub-lethal concentrations for 3 days influences the response of different Staphylococcus spp. to hBD-3, and if this treatment reduces the potency of the natural defence.
Methods

Collection and growth of the bacterial strains
Six different isolates of skin bacteria were taken from different skin sites of two healthy, male volunteers (volunteer numbers 16 and 19) . From volunteer 16, we obtained two isolates from the upper back after the application of 89.5% (v/v) propan-1-ol and one skin isolate from the abdomen. In addition, two isolates were taken from the forehead of volunteer 19 after the application of 70% (v/v) propan-2-ol or 89.5% (v/v) propan-1-ol and one isolate was collected from the abdomen. The skin bacteria were collected using a swab method which has previously been described [13] . The skin bacteria were grown aerobically on casein-peptone soymeal-peptone (CASO) agar at 37°C for 48 h; thereafter, six single colonies were isolated, plated separately on CASO agar and aerobically incubated at 37°C for 24 h. For susceptibility testing, isolate 19/3, 16/2 and 16/3 were excluded from the study due to clonal identity (see later); the chosen isolates are listed in Table 1 . The bacteria were stored at −74°C using the CRYOBANK system (Mast Diagnostica Laboratoriumspräparate GmbH, Reinfeld, Germany).
Identification and characterisation of skin isolates
All isolates were Gram-positive; they were characterised by macroscopic and microscopic analyses. They were plated on CASO agar, sheep blood agar and selective agar plates (kanamycin and Mannitol salt). The presence of clumping factor, protein A and capsular polysaccharide was analysed with the Staphytect Plus™ test (Oxoid Deutschland GmbH, Wesel, Germany). For genotypic characterisation of the clonal relationship of the skin isolates, pulsed-field gel electrophoresis (PFGE) analysis using the criteria of Tenover et al. [24] was used (data not shown).
Bacterial species
The following staphylococcal type strains were used to amplify the respective intragenic gyrA fragments for sequence-based identification of skin isolates: S. aureus ATCC 6538, S. warneri ATCC 27836, S. warneri ATCC 155, S. capitis subsp. capitis ATCC 27841, S. epidermidis ATCC 14990.
Primers
Based on a multiple DNA sequence alignment of gyrA genes from different staphylococcal species, regions of high homology were chosen for the design of a primer pair to be used for polymerase chain reaction (PCR) amplification and for cycle sequencing of the quinolone resistance-determining region (QRDR). The primer pair includes 5′-primer gyrA_ [A70V]_5′_:+73_Sau 5′-TATGCGATG(A/T)(G/C)(A/C/T) GTTAT(A/C/T)GT-3′ (corresponding to nts. 73 to 82) and 3′-primer gyrA_[A640R]_3′_+661_Sau 5′-CCGTTGG(A/G) AA(A/G)TC(A/T)GG(A/C/T)CC-3′ (complementary to nts. 661 to 680), giving rise to a 608-bp intragenic PCR fragment. For cycle sequencing reactions, primer gyrA-A70V was used.
PCR conditions
Template DNA was isolated from three to five individual colonies of a type strain of the respective staphylococcal species and from skin isolates of volunteers using the QIAGEN Tissue Purification Kit® according to the manufacturer's protocol. Using 2.5 µl of template DNA in a total volume of 50 µl, respective intragenic fragments of the gyrA gene were amplified using the following reaction conditions: 1.25 mM MgCl 2 , 30 (40) pMol of each primer of gyrA 50 µmol dNTPs, 2.5 U Taq DNA polymerase (NE Biolabs, Germany) in reaction buffer supplied by the manufacturer. After an initial denaturation at 94°C for 5 min, primer annealing followed for 45 s at 50°C , DNA synthesis at 72°f or 1 min and denaturation at 94°C for 30 s over 35 cycles. PCR fragments were purified using the Macherey-Nagel NucleoSpin® Extract II kit according to the manufacturer's protocol. Samples were eluted with 50 µl of a 1:10 diluted EB-Puffer® (QIAGEN, Hilden, Germany). Between 40 and 80 ng of purified PCR product were used for the subsequent cycle sequencing reactions, which were run for 30 cycles (denaturation at 96°C for 20 s, annealing at 50°for 5 s and polymerisation at 60°C for 4 min, in a total volume of 20 µl using 10 pMol of the respective 5′-primer, Quick Start Kit (Beckman Coulter Krefeld, Germany), according to the manufacturer's instructions.
After completing the cycle sequencing reactions, DNA fragments were precipitated by adding 5 µl of precipitation solution (2 µl 3 M sodium acetate solution pH 5.2, 2 µl 100 mM EDTA pH 8.0 and 1 µl Glycogen) and mixed with 60 µl of absolute ethanol. Precipitated DNA was collected by subsequent centrifugation (15 min, 15,000 rpm, room temperature) and washed with ethanol (70%). Samples were air-dried and resuspended in 30 µl SLS® (BeckmanCoulter, Krefeld, Germany) and immediately cooled to 4°C before applying the DNA samples to the capillary electrophoresis column. To assign an isolate to a staphylococcal species, the DNA sequence determined for the respective gyrA gene fragment was aligned to a database of staphylococcal reference strains yielding homologies equal to or higher than 90%, whereas homologies below 90% were found for gyrA gene fragments from different species.
To assign skin isolate 16/1 to a bacterial species without doubt, an API ID 32 Staph test (bioMérieux Deutschland GmbH, Nürtingen, Germany) was carried out for biochemical identification.
Determination of oxacillin and chlorhexidine susceptibility
The minimum inhibitory concentration (MIC) determinations were carried out by microdilution [25] . The tests were carried out with the skin isolates S. aureus ATCC6538 and S. epidermidis ATCC12228. S. aureus ATCC29213 was used as the control strain and oxacillin (InfectoStaph, Infectopharm) was used as the reference antibiotic. The oxacillin-containing Mueller-Hinton broth (DIFCO, Augsburg, Germany) was supplemented with 3% NaCl.
Preparation of test bacteria and time-kill analyses with hBD-3
All tubes and plates were incubated aerobically at 37°C. The following procedure was carried out separately for each isolate.
Day 0 The second passage of each test strain was generated by incubation on CASO agar for 24 h. A quantity of 9.9 ml of tryptic soy broth (TSB) without any additional substances (control without CHG exposure) as well as 9.9 ml TSB containing different concentrations of CHG were inoculated with 100 μl of bacterial suspension. Both were incubated for 24 h. Days 2 and 3 After overnight incubation, each tube was shaken and screened for visible growth. A quantity of 100 μl of the control sample was added to 9.9 ml of TSB without any additional substances (second and third passage of control in broth). From the CHG-containing samples, the sample with the highest CHG concentration and visible growth was chosen. For the inoculation of 9.9 ml TSB containing CHG (as described above), 100 μl of the suspension was taken for each sample. The control and the CHG dilution series were again incubated for 24 h. Day 4 A quantity of 100 μl of the control sample and the sample with the highest CHG concentration with visible growth were plated homogenously on CASO agar containing 0.1% L-histidine, 0.3% lecithin and 3% polysorbate 80, and incubated for 24 h.
Day 5
The lyophilised recombinant hBD-3 (RELIATech, Braunschweig, Germany) was solubilised and diluted in aqua bidest (pH 6.5-6.8), as recommended by the manufacturer of the peptide, to obtain a 10 μl solution containing the defined concentration of hBD-3 (Table 2) . To ensure identical conditions for each test, the reconstituted hBD-3 was stored in cooled metal blocks until the test was performed. The tests were carried out within several minutes after preparing the diluted peptide solutions. Before the tests started, preliminary tests were carried out to find suitable hBD-3 concentrations for each isolate, to enable us to carry out time-kill studies at 1.5 and 3 h. For each strain, two specific hBD-3 concentrations were chosen, and it was predefined that the high concentration must contain four-fold more hBD-3 than the low concentration.
Colonies on each CASO agar plate were rinsed off with 10 ml of phosphate buffer (10 mM), the suspensions were transferred into sterile glass cylinders with glass pearls and homogenised by mixing for at least 10 min. Each suspension was diluted with phosphate buffer (10 mM) to an optical density of 0.125-0.175 as described above. A dilution series was plated in duplicate to determine the baseline bacterial density.
All tests were carried out with the CHG-exposed and non-exposed bacteria. Tests in solution were carried out in triplicate as follows:
-100 μl of the 1:10 dilution of the adjusted suspension of bacteria was added to each of the batch so that a total volume of 1 ml was obtained in all cases. -Control test: 900 μl phosphate buffer -Susceptibility test with low hBD-3-concentration: 10 μl low concentration of hBD-3 solution in 890 μl phosphate buffer (10 mM) -Susceptibility test with high hBD-3-concentration:
10 μl high concentration of hBD-3 solution in 890 μl phosphate buffer (10 mM)
After the exposure times of 1.5 and 3 h, dilution series were prepared with TSB supplemented with 3% polysorbate 80, 0.3% lecithin, 0.1% L-histidine and 0.1% L-cysteine; 100-μl aliquots were plated in duplicate on CASO agar containing 0.1% L-histidine, 0.3% lecithin and 3% polysorbate 80, and incubated for 48-72 h. The number of colonyforming units (CFUs) were counted after incubation and transferred into log 10 values.
Statistical analysis
All computer-based statistical calculations were performed with SPSS 13.0 or 15.0 (SPSS Inc., Chicago, IL, USA).
All plates with CFU between 15 and 300 were evaluated. The results were evaluated as arithmetic means of the log 10 values of each duplicate analysis. When the results of two different dilution steps were within the defined CFU range, the weighted means were calculated.
The log 10 reduction for both exposure times was calculated by subtracting the means of the triplicate analyses of the log 10 CFU count for hBD-3-treated samples from the mean log 10 CFU count of the phosphate buffer control. The change in response to hBD-3 was determined by comparing the mean log 10 reduction at 1.5 h as well as 3 h in exposed and non-exposed (control) bacteria.
A t-test was carried out to determine the differences between the log 10 reduction of the CHG-exposed and nonexposed samples after 1.5 and 3 h for both test concentrations of hBD-3.
Results
Characterisation of isolates and strains
Two of the isolates obtained from the forehead of volunteer 19 (19/2 and 19/3) and all three isolates from two different body sites of volunteer 16 (16/1 to 16/3) showed identical PFGE patterns (data not shown), although they were obtained from different body sites and, respectively, from different test areas of the forehead.
The chosen isolates varied in their ability to obtain agglutination with the Staphytect Plus™ test (Oxoid Deutschland GmbH, Wesel, Germany). Only isolate 16/1 showed a positive agglutination reaction. All skin isolates grew on Mannitol salt agar and fermented Mannitol. None of the skin isolates showed haemolysis on blood agar. All skin isolates were susceptible to oxacillin (MIC<8 μg/ml). The MICs for chlorhexidine were comparable for all tested strains (MIC 0.5-2 μg/ml).
The comparison of the resulting DNA sequences with those determined for the staphylococcal reference strains revealed that isolates 19/1 and 19/2 should be assigned to S. capitis subsp. capitis (homology>98%). The DNA sequencing results of an internal 284-bp PCR fragment of the gyrA gene obtained from isolate 16/1 revealed sequence homologies of 87, 88, 90 and 89% compared to the reference strains of S. aureus, S. epidermidis, S. warneri and S. capitis subsp. capitis, respectively. The API ID 32 Staph test (bioMérieux Deutschland GmbH, Nürtingen, Germany) confirmed the gyrA gene sequence-based identification of isolate 16/1 as S. warneri with %id=99.9% and t= 0.95; no biochemical results were found to be against the assignment to this species. The concentrations of the CHG exposition as well as the results for the hBD-3 time-kill tests are presented in Table 2 .
A two-fold decrease in CHG susceptibility was detected for two isolates (19/2 and 16/1) after 3 days exposure to CHG. No change in susceptibility was detected for 19/1 and S. epidermidis ATCC 12228. However, we found only low turbidity after the first incubation of S. aureus ATCC 6538 with 1 μg/ml CHG and an increasing susceptibility in the second passage.
The results for the hBD-3 time-kill testing were inconsistent ( Table 2 ). In 13 out of 20 experiments, we found no statistically significant difference in response to hBD-3 with and without previous CHG exposure. In four cases, hBD-3 killed significantly fewer bacteria which had been previously exposed to CHG, whereas in one of these, the difference was less than 0.1 log scale. We found a significant decrease in hBD-3 susceptibility for both exposure times only for S. capitis 19/2 and after 3 h of exposure to hBD-3 for S. warneri 16/1. In three cases, more CHG-exposed bacteria were killed by hBD-3 compared to non-exposed bacteria, although in one case, the difference was less than 0.4 log scales (Fig. 1) .
Discussion
We found no clear evidence that exposure to sub-lethal concentrations of CHG for 3 days influenced the response of Staphylococcus spp. to hBD-3. Our results show variable changes in time-kill studies for different strains. In strains that showed a decrease in CHG susceptibility within the 3-day exposure period (S. capitis 19/2 and S. warneri 16/1), we found a significant decrease in response to hBD-3. This may indicate a link between CHG adaptation and a decrease in response to hBD-3. Further investigation is needed to verify this hypothesis.
Exposure to CHG has been reported to result in adaptation, e.g. in skin bacteria [23] , and, thus, changes susceptibility to different antibiotics and biocides [15] [16] [17] [18] [19] [20] [21] [22] . Therefore, an influence of previous exposure to CHG on susceptibility to hBD-3 is possible due to the structural properties of both substances and their comparable mode of action. A negatively charged cell surface is essential for the affinity of both cationic antimicrobials to Gram-positive bacteria, to allow electrostatic interactions between the molecules and the cell surface [3, 26] . For hBD-3 as well as CHG and other cationic antibiotics, changes in susceptibility on the basis of alteration of the dlt operon and, therefore, the cell surface charge by D-alanylation of teichoic acids is described in the literature [27] [28] [29] . For example, dltDdeficient mutants of Lactobacillus casei were more susceptible to CHG [29] . Peschel et al. demonstrated for S. aureus and S. xylosus that inactivation of the dlt operon resulted in enhanced susceptibility to defensins (human defensins HNP1-3) [28] . It is also described that Gram-positive bacteria are able to sense the existence of sub-inhibitory concentrations of antimicrobial peptides like hBD-3 to control different resistance mechanisms. Li et al. showed that exposure to sub-inhibitory concentrations of hBD-3 resulted in a significant upregulation of the expression of the dlt operon and a subsequent increase in D-alanylation of teichoic acids in S. epidermidis [30] . A comparable mechanism with a change in the bacterial surface charge to resist human β-defensins is also discussed for Gramnegative bacteria [31] . Therefore, a correlation between the mechanism of bacteria to circumvent the natural host defence of the skin caused by AMPs and the mechanism for resistance to cationic antimicrobials, e.g. CHG, is likely.
Another mechanism which may also play a role in resistance to hBD-3 as well as CHG is the expression of MDR efflux pumps. Huet et al. demonstrated that, in S. aureus, single as well as multiple-step exposure to biocides, which were comparable to CHG, resulted in an increase in the MIC for CHG and multiple other biocides, mostly due to an upregulation of the gene expression of different MDR efflux pumps like mepA and norA [32] . These results showed that single exposure to biocides may result in a change in cell regulatory mechanisms and, therefore, a change in susceptibility. The role of an MDR efflux-related increase in MIC and skin disinfection with CHG is also discussed by DeMarco et al. [33] . Efflux mechanisms are also relevant for decreasing susceptibility, for example of Treponema denticola, to hBD-3 [34] , although current research findings suggest that MDR efflux pumps do not play an important role in hBD-3 resistance [35] .
With regard to our results, we found considerable differences in response to different concentrations of hBD-3 between the tested strains. Therefore, we assume that susceptibility is not only species-specific but also strain-specific. For S. capitis 19/2 and S. epidermidis ATCC12228, the difference in response to hBD-3 of CHG-exposed and non-exposed bacteria at a concentration of 0.125 μg/ml at 1.5 h was statistically significant, but the log 10 differences of the RF values were less than 0.35 log scales. Therefore, the biological relevance of these differences remains debatable.
On the basis of our results, we could not find any evidence that residual CHG has a negative influence on the host immune defence, e.g. when it is used for catheter site care. Therefore, a concluding evaluation regarding the clinical relevance of these findings is not yet possible. On the one hand, further discussion may be needed if studies verify that CHG-adapted bacteria show a reduced response Left side: mean log CFU/ml after 1.5 and 3 h exposure to different hBD-3 concentrations with and without previous exposure of bacteria to sub-lethal concentrations of CHG; PB=phosphate buffer; CHG (+)=CHG-exposed; CHG (−)=non-CHG-exposed. Right side: difference in log 10 reduction of CHG-exposed and non-exposed bacteria after 1.5 and 3 h exposure to hBD-3; * = significant difference; (*)=significant difference but log 10 difference<0.4 to hBD-3; however, it should be kept in mind that the tested CHG concentrations were much lower than the concentrations used in clinical practice. On the other hand, a beneficial effect of CHG has been shown in the prevention of catheter-related bloodstream infections, and a synergism with hBD-3 has been demonstrated. If a significant influence of CHG exposure on hBD-3 susceptibility cannot be confirmed, the presence of both substances on the skin in combination may contribute to the positive effect seen in the prevention of catheter-related bloodstream infections due to a potentially synergistic effect against skin bacteria. However, the power of this study is limited due to the small number of strains tested. Moreover, different results may be obtained with a longer CHG exposure time prior to hBD-3 time-kill tests. It is possible that a time period of 3 days is not long enough to select bacteria which show changes in response to hBD-3. Further investigation with more test strains and other bacterial species is needed to clarify whether CHG-adapted bacteria are significantly less susceptible to hBD-3. Although we carried out all tests in triplicate and found comparable results in the tests for the strains which showed a decrease in susceptibility after CHG exposure, it would be interesting to see if the same results can be found with another sample of the same peptide. Our data, however, do not allow us to give an answer because all tests were carried out with the same batch of hBD-3. If these findings can be verified by other studies, it would be interesting to determine if comparable or even identical resistance mechanisms are the cause.
Conclusions
Apparent differences in the response to human β-Defensin-3 (hBD-3) were found in bacteria which showed a decrease in susceptibility after exposure to sub-lethal concentrations of chlorhexidine digluconate (CHG) for 3 days. However, we found no consistent evidence that 3 days of exposure to CHG changed the response of five Staphylococcus spp. to hBD-3. The use of CHG for skin antisepsis is, based on our data, unlikely to change the natural defence of hBD-3.
